Anne B. Curtis, MD, SUNY Distinguished Professor in the Jacobs School of Medicine and Biomedical Sciences has received the ...

The results of the MIROCALS randomized clinical trial have shown that adding low-dose interleukin-2 (IL2LD) to standard ...

A new study suggests that people who are at risk for rare genetic forms of frontotemporal dementia should consider being tested for a common gene variant that can protect them against the group of ...

Published in the journal Brain, the researchers recommend accounting for the protective variant in clinical trials that ...

Long-term clinical evaluation represents key advancement following successful first-in-human studyRUTHERFORD, N.J., May 13, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or ...

Xmoor Pharma has entered into a strategic partnership with KU Leuven to support a new cell and gene therapy hub.

Presented new preclinical data for OP-3136 at the American Association for Cancer Research (AACR) Annual Meeting in April, demonstrating anti-tumor activity in pre-clinical in vitro and in vivo ...

Compass Therapeutics' tovecimig shows promise in biliary cancer, boasting a 17.1% response rate. Despite high risks, I ...

Daré will host a conference call and live webcast today, May 13, 2025, at 4:30 p.m. Eastern Time to review financial results ...

Xenon Pharmaceuticals Inc (XENE) reports robust cash reserves and advances in epilepsy and psychiatry studies, despite minor ...

A clinical trial has found that low-dose interleukin-2 is both safe and effective for use on people with motor neuron disease ...